Introduction
============

Cancer is the leading cause of death in Western countries. Colorectal cancer (CRC) has the highest incidence (both sexes) and is the second leading cause of cancer death after lung cancer [@OR1089-1] [@OR1089-2] . Colon cancer screening programs aim to reduce mortality by detecting advanced adenomas or colon cancer at an early stage (I or II).

Colonoscopy is one of the key tools in any CRC screening strategy. It allows visualization of the entire colon, detection and removal of adenomas, and diagnosis and treatment of CRC. The adenoma detection rate (ADR) has become the most important indicator of the quality of colonoscopy because it is directly related to key outcome indicators, such as interval cancer rates [@JR1089-3] . To ensure adequate quality, screening colonoscopies should comply with established minimum quality standards [@JR1089-4] . In particular, good or excellent bowel cleansing is essential, poor cleansing being known to increase risk of complications, such as bleeding and perforation.

An academic or university hospital is a medical center that provides clinical education and training to physician residents in various specialties (e. g., gastroenterology) and other health professionals under a supervising (attending) physician. In general, these centers are considered tertiary hospitals.

Most studies analyzing the quality of colonoscopy are based on data from academic hospitals or tertiary hospitals. It is therefore very important to know whether the quality of colonoscopy in a population screening program is the same in different types of hospitals. In this context, the purpose of this study was to determine the quality of colonoscopies and detection of lesions in a screening program using fecal immunochemical testing by hospital type.

Patients and methods
--------------------

### Study population and interventions

An observational nested study was conducted to investigate factors related to quality of colonoscopy in a screening program. The colorectal cancer screening program in the Basque Country (Spain) was developed and progressively rolled out from 2009 to 2014, reaching a coverage of 96 % of the target population (an estimated 586,700 people) [@JR1089-5] [@JR1089-6] . Individuals aged 50 to 69 were offered a biennial fecal immunochemical test (FIT). FITs (OC-Sensor) were considered positive if samples contained ≥ 20 µg Hb/g feces.

We included all colonoscopies performed in the screening program after a positive FIT between January 2009 and September 2016. During that period, 1,377,398 patients accepted invitations for FIT tests and 56,548 obtained positive results. Among these cases, 52,241 patients underwent colonoscopy (92.3 % compliance rate). All colonoscopies were included in our analysis, except those performed in private clinics (n = 3,482), because of difficulties monitoring some quality parameters and complications.

The 13 public hospitals that conducted the colonoscopies analyzed were classified as academic or non-academic. All the academic hospitals were referral centers for advanced endoscopy (echoendoscopy, endoscopic retrograde cholangiopancreatography, etc.) that provide training to physician residents in gastroenterology and are affiliated with a medical school or university. In general, these hospitals have more than 300 beds and serve a population of over 100,000. Other hospitals were defined as non-academic. Overall, seven of the participating hospitals were classified as non-academic and six as academic.

Colonoscopies were performed under sedation and almost always by experienced specialists who conduct at least 300 colonoscopies per year. On some occasions, in the academic hospitals, trainees perform the colonoscopies supervised by staff doctors (with the aforementioned level of experience). In the event of polyps being found, a staff doctor should take over, confirming type and size of lesions and as appropriate removing them. All patients were followed-up with close coordination between primary care and specialized units. Each case was coded by the coordinating office staff following standard European Union guidelines and Spanish Network consensus recommendations [@JR1089-7] [@OR1089-8] .

For all colonoscopies across the hospitals participating in the study, magnesium citrate with sodium picosulfate (Citrafleet) was used for bowel preparation, splitting the dose between the day before and the day of colonoscopy. Further, in all hospitals, sedation was achieved with propofol by an anesthetist or endoscopist. Colonoscopies were all performed using standard white light video equipment and none using prescheduled panchromoendoscopy.

Histology of all lesions detected was evaluated by experienced pathologists specialized in gastrointestinal oncology in accordance with quality standards set out in the European guidelines [@JR1089-9] . The following were recorded: the furthest point reached in the colonoscopy, adequacy of bowel preparation, and characteristics and location of any polyps. Adenomas ≥ 10 mm, with a villous component (i. e., tubule-villous or villous adenoma) and/or with severe/high-grade dysplasia were classified as advanced adenomas (AAs) [@JR1089-9] , and other adenomas as non-advanced or low-risk adenomas (LRAs). Advanced neoplasia (AN) was defined as CRC plus AA. Tumors were staged according to the TNM classification system published in the American Joint Committee on Cancer Staging Manual [@BR1089-10] . Finally, participants were classified and then assigned to treatment according to the most advanced lesion found. Stage I or II cancer was considered early-stage disease. The proximal colon was considered to include the cecum, ascending colon, or transverse colon. Individuals were classified as having proximal adenomas if any adenomas were located in the proximal colon and distal adenomas if adenomas were found only in the distal colon.

For identification of interval cancers, detected prior to the next scheduled screening appointment, we developed an evaluation process in which screening registries and cancer registries were linked, including data on causes of death [@JR1089-11] [@JR1089-12] [@JR1089-13] . Interval post-colonoscopy colorectal cancer was defined as CRC diagnosed after a screening or surveillance exam in which no cancer was detected and before the date of the next recommended exam [@JR1089-11] .

Bowel cleansing was classified following the Boston Bowel Preparation Scale (BBPS) to evaluate adequacy of preparation [@JR1089-14] [@JR1089-15] . With that scale, each segment of the colon is graded from 0 to 3, depending on how well the colon mucosa can be seen and an aggregate score is obtained by summing the scores for all three segments, yielding a score between 0 and 9. In this study, total BBPS scores \> 6 were considered to indicate successful bowel preparation.

Cecal intubation was defined as insertion of the endoscope tip to a point proximal to the ileocecal valve such that the entire cecal pole, including the medial wall (located between the ileocecal valve and appendiceal orifice), is visualized and explored. Colonoscopies that did not reach the cecum were considered inconclusive or incomplete.

All cases were followed and linked with hospital discharges and emergency care to detect any severe or minor complications within 30 days. Bleeding, perforation, and other conditions were considered severe complications if they required the patient to remain in hospital after the procedure for at least 24 hours or, in patients discharged after of colonoscopy, required readmission within 30 days after the procedure. These other conditions included postpolypectomy syndrome (abdominal pain without perforation or microperforation) and respiratory or heart failure related to sedation. Hypotension, arrhythmias, or transient hypoxemia were considered mild complications. Other data collected were: history of abdominal surgery, anticoagulant or antiplatelet use, number of polyps resected, existence of diverticula, and body mass index.

This study was approved by the local ethics committee. All participants provided written informed consent.

Data analysis
-------------

Categorical variables were described using frequencies and percentages and continuous variables using means and standard deviations and/or medians and interquartile ranges depending on characteristics of the data distribution. Categorical variables were compared with the chi-square test or Fisher\'s exact test. Multivariate logistic regression was used to estimate risk of injury during screening by hospital type. A *P* value less than 0.05 was considered to indicate statistical significance. Finally, 95 % confidence intervals (CIs) were calculated in all cases. All the statistical analysis was performed with IBM SPSS, Statistics for Windows, Version 22.0 and STATA 13.

Results
=======

During the study period, 48,759 individuals underwent colonoscopy in participating hospitals, 34,616 in academic hospitals and 14,143 in non-academic hospitals ( [Table 1](#TB1089-1){ref-type="table"} ). A total of 31,693, 13,653 and 3,413 colonoscopies were performed in first, second and third screening rounds, respectively. The cecal intubation rate recorded was 96.2 %, significantly higher in non-academic hospitals than academic hospitals (97 % vs 95.9 %; odds ratio \[OR\] 1.52, 95 % confidence interval \[CI\] 1.38 -- 1.69; *P*  \< 0.001) and also significantly higher in men than women (96.4 %, 95 % CI 96.4 -- 96.7, vs 95.8 %, 95 % CI 95.7 -- 96; *P*  \< 0.001). Rates of adequate colonic preparation were 88.3 % (95 % CI 87.9 -- 88.5), being lower in academic hospitals (86.4 % vs 93 %; OR 0.48, 95 % CI 0.45 -- 0.51; *P*  \< 0.001), but unlike the cecal intubation rate, higher in women than men (89.4 %, 95 % CI 89 -- 89.9, vs 87.6 %, 95 % CI 87.2 -- 88.1; *P*  \< 0.001).

###### General characteristics of colonoscopies by hospital type.

                                   Total N           Academic hospitals N   Non-academic hospitals N   Odds ratio (95 % CI)   *P* value
  -------------------------------- ----------------- ---------------------- -------------------------- ---------------------- -----------
                                   48,759            34,616                 14,143                                            
  Sex (males)                      29,109 (59.7 %)   20,596 (59.5 %)         8,500 (60 %)              0.98 (0.94 -- 1.02)    0.2
  Aged, years                                                                                                                 
  49 -- 54                         10,971 (22.5 %)    7,789 (22.5 %)         3,406 (22.4 %)            ref                    
  55 -- 59                         11,507 (23.6 %)    8,204 (23.7)           3,558 (23.4 %)            1.00 (0.95 -- 1.07)    0.3
  60 -- 64                         12,755 (26.2 %)    9,104 (26.3 %)         3,953 (26 %)              1.00 (0.95 -- 1.06)    0.25
  65 -- 69                         13,409 (27.5 %)    9,519 (27.5 %)         4,303 (28.3 %)            0.97 (0.92 -- 1.02)    0.23
  Cecal intubation                 46,906 (96.2 %)   33,187 (95.9 %)        13,719 (97 %)              0.48 (0.38 -- 0.69)     \< 0.001
  Colonic preparation (adequate)   43,054 (88.3 %)   29,901 (86.4 %)        13,153 (93 %)              0.48 (0.45 -- 0.51)     \< 0.001
  Low risk adenoma                  8,670 (17.8 %)    6,160 (17.8 %)         2,510 (17.7 %)            1.00 (0.95 -- 1.06)    0.9
  Advanced adenoma                 19,942 (40.9 %)   13,767 (39.8 %)         6,175 (43.7 %)            0.85 (0.82 -- 0.89)     \< 0.001
  Colorectal cancer                 2,607 (5.3 %)     1,900 (5.5 %)            707 (5 %)               1,10 (1.01 -- 1.21)    0.03
  Advanced neoplasia               22,549 (46.2 %)   15,667 (45.3 %)         6,882 (48.7 %)            0.87 (0.84 -- 0.91)     \< 0.001
  Complication                        602 (1.2 %)       431 (1.2 %)            171 (1.2 %)             1.03 (0.86 -- 1.23)    0.7

A total of 19,942 (40.9 %) cases of AA and 2,607 (5.3 %) of CRC were detected, representing a total of 22,549 (46.2 %) cases of AN, while 8,670 (17.8 %) patients had low risk adenomas. The ADR was 64 % overall, the rate being significantly higher in non-academic than academic hospitals (66.4 % vs 63.1 % *P*  \< 0.001). Rates of AN detected per screening round were 50 %, 40 % and 40 % in the first, second and third round, respectively. The rate of AN detection was lower in academic hospitals (45.3 % vs 48.7 %; OR 0.87, 95 % CI 0.84 -- 0.91; *P*  \< 0.001). Regarding stage of diagnosis, 70 % of CRCs detected were at an early stage (I-II) at time of diagnosis. Overall, 57 % of T1 cancers were treated by endoscopy alone. No significant differences were found by hospital type, either in diagnosis of early-stage CRC or in number of patients with CRC treated by endoscopy ( [Table 2](#TB1089-2){ref-type="table"} ). CRC was diagnosed after colonoscopy in 13 patients in the academic hospital group (0.26 cases × 1000 colonoscopies); in contrast, there were no cases of post-colonoscopy CRC in non-academic hospitals. [Table 3](#TB1089-3){ref-type="table"} describes characteristics of patients with interval cancer after colonoscopy.

###### Stage of cancer and treatment by hospital type.

                                              Academic hospitals 1,900   Non-academic Hospitals 707   Odds ratio (95 % CI)   *P* value
  ------------------------------------------- -------------------------- ---------------------------- ---------------------- -----------
  Colorectal cancer stage                                                                                                    
  I                                           1,006 (52.9 %)             373 (52.7 %)                 ref                    
  II                                             324 (17.1 %)            113 (16.0 %)                 1.06 (0.83 -- 1.36)    0.6
  III                                            443 (23.3 %)            156 (22.1 %)                 1.05 (0.85 -- 1.31)    0.6
  IV                                             117 (6.2 %)              51 (7.3 %)                  0.85 (0.60 -- 1.20)    0.4
  Unknown                                         10 (0.5 %)              14 (2 %)                    0.27 (0.12 -- 0.60)     \< 0.001
  Post-colonoscopy cancer (interval cancer)       13 (0.26 cases/1000)     0 (0 cases/1000)           5.24 (0.69 -- 39.92)   0.1
  Treatment                                                                                                                  
  Endoscopic                                     575 (30.3)              210 (30.2 %)                 ref                    0.4
  Surgical                                    1,131 (59.7 %)             403 (57.9 %)                 1.03 (0.84 -- 1.25)    0.8
  Other/lost to follow-up                        186 (9.8 %)              82 (11.7 %)                 0.83 (0.60 -- 1.12)    0.2

###### Characteristics of patients with interval cancer after colonoscopy.

  Cases     Age   Sex   FIT (ng/mg feces)   Colorectal cancer stage   Localization   Size (cm)   Time from colonoscopy (months)   Resection of polyps in the same zone   Quality of colonoscopy   Dead
  --------- ----- ----- ------------------- ------------------------- -------------- ----------- -------------------------------- -------------------------------------- ------------------------ ------
  Case 1    66    M     158                 III                       Rectum         6           24                               No                                     Poor                     No
  Case 2    65    F     825                 IV                        Sigmoid        --          18                               No                                     Good                     No
  Case 3    58    M     13,042              IV                        Transverse     --          48                               No                                     Good                     Yes
  Case 4    64    M     1,402               III                       Sigmoid                    38                               Yes                                    Poor                     No
  Case 5    59    F     4,357               III                       Cecum          5.5         33                               No                                     Good                     Yes
  Case 6    58    F     13,235              I                         Cecum          1.5          7                               Yes                                    Good                     No
  Case 7    62    F     107                 IV                        Transverse     --          14                               No                                     Good                     No
  Case 8    64    M     100                 II                        Descending     4           46                               Yes                                    Good                     No
  Case 9    61    M     1,194               IV                        Cecum          7           23                               No                                     Good                     Yes
  Case 10   68    M     396                 III                       Rectum         6           21                               No                                     Good                     No
  Case 11   58    M     188                 I                         Sigmoid        2.5         22                               No                                     Good                     No
  Case 12   60    F     953                 II                        sigmoid        4           21                               No                                     Good                     No
  Case 13   63    M     119                 III                       Sigmoid        3           42                               No                                     Poor                     No

M, male; F, female

The total complication rate was 1.2 % (602 patients), with no significant differences by hospital type or age group. Hemorrhage was the most common type of complication, occurring in 1/147 colonoscopies, and was more frequent in academic hospitals ( [Table 4](#TB1089-4){ref-type="table"} ). Men had a higher risk of bleeding than women, with an OR of 1.86 (95 % CI, 1.31 -- 2.65; *P*  = 0.001). Bleeding was also associated with polyp size ≥ 2 cm and a larger number of polyps. Perforation occurred in 1 /329 cases, and again, men were at higher risk than women (OR, 1.58; 95 % CI, 1.06 -- 2.33; *P*  = 0.022). Perforation was also associated with colonic diverticula, poor preparation, removal of large polyps (≥ 2 cm) and previous abdominal surgery. Lastly, the rate of other complications requiring hospitalization such as post-polypectomy syndrome or those related to sedation was 1/799 colonoscopies, with a significantly higher risk in women than men (OR, 2.21; 95 % CI, 1.30 -- 3.77; *P*  = 0.003). One death was recorded within 30 days after screening colonoscopy due to peritonitis following perforation.

###### Complications by hospital type.

                Academic hospitals no. of colonoscopies; 34,616   Non-academic hospitals no. of colonoscopies; 14,143   *P* value
  ------------- ------------------------------------------------- ----------------------------------------------------- -----------
  Total         431 (1.2 %)                                       171 (1.2 %)                                           0.4
  Serious       389 (1.1 %)                                       150 (1 %)                                             0.2
  Hemorrhage    245 (63.1 %)                                       85 (55.5 %)                                           \< 0.05
  Perforation   103 (26.8 %)                                       45 (29.4 %)                                          0.3
  Sedation        8 (1.9 %)                                         2 (1.2 %)                                           0.4
  Other          32 (7.4 %)                                        18 (10.5 %)                                          0.3
  Death           1 (0.2 %)                                       --                                                    0.4
  Non-serious                                                                                                           
  Sedation       33 (7.7 %)                                        19 (11.1 %)                                          0.4
  Other           9 (2.1 %)                                         2 (1.2 %)                                           0.2

Discussion
==========

In our study, in screening colonoscopies after fecal occult blood testing, we observed a higher ADR when colonoscopy was performed in non-academic hospitals. Specifically, the ADR in our population screening program after a positive FIT was 64 % overall, with rates of 66.4 % in non-academic and 63.1 % in academic hospitals, respectively. ADR is the main quality indicator for colonoscopy and is inversely associated with risks of interval colorectal cancer, advanced-stage interval cancer, fatal interval cancer and mortality [@JR1089-16] [@JR1089-17] . Further, it is a marker that indirectly reflects other surrogate quality indicators such as quality of bowel preparation, colonoscopy completeness, and withdrawal time.

It has been suggested that ADR after a positive FIT should be greater than 40 % [@JR1089-4] . In the COLONPREV clinical trial comparing FIT with colonoscopy in CRC population screening in middle-aged people, we observed an ADR of 31 % in the colonoscopy group and 55 % (range, 21 % -- 83 %) in the FIT group (17); in that study, individuals with a hemoglobin concentration ≥ 15 mg Hb/g feces were invited for colonoscopy. These findings are concordant with studies of other CRC screening programs based on fecal occult blood testing, which have found similar mean ADRs: 44.8 % in the Italian screening program (using FITs) and 46.5 % in the National Health Service Bowel Cancer Screening Program in England (using guaiac-based tests) [@JR1089-9] [@JR1089-18] .

Interval CRC after colonoscopy is another fundamental factor to assess quality of colonoscopy with reported rates ranging from 0.3 to 1.7 cases per 1,000 colonoscopies [@JR1089-11] [@JR1089-19] [@JR1089-20] . In our study, we found 0.26 cases per 1000 colonoscopies. There is agreement that there are three main explanations for post-colonoscopy CRC: missed advanced neoplasia, new lesions and incompletely resected lesions. The most important factor related to missed advanced neoplasia is the ADR, which in turn depends on cecal intubation rate, withdrawal time, and colon cleansing [@JR1089-15] [@JR1089-18] [@JR1089-21] [@JR1089-22] [@JR1089-23] [@JR1089-24] [@JR1089-25] [@JR1089-26] [@JR1089-27] . All these factors are interrelated. In general, in these studies, ADR has been seen to correlate with cecal intubation rate and degree of cleansing: the better the cleansing, the higher the ADR; and the higher cecal intubation rate, the higher the ADR.

If physicians with lower ADRs are also less likely to completely resect polyps, the high subsequent risk of cancer among their patients may be due, at least in part, to incomplete resection rather than decreased detection alone [@JR1089-16] . Notably, in one-quarter of cases of interval CRC in our study, cancer developed in a colonic segment where a polypectomy had been performed during the prior colonoscopy. We underline that to decrease post-colonoscopy CRC, there is a need, in particular, for measures to: enhance visualization, particularly on proximal folds; increase cecal intubation rates; improve visualization of polyp resection margins; and improve detection of serrated pathway lesions, together with refined surveillance intervals and better training and quality assurance [@JR1089-4] .

Our findings could be explained at least partially by trainee physicians having performed colonoscopies without adequate supervision or longer withdrawal times at non-academic hospitals. Unfortunately, withdrawal time is a parameter about which data were not collected systematically in our screening program. Another factor that might explain our findings would be a higher level of motivation among staff (doctors and nurses) in non-academic hospitals in relation to screening colonoscopies and in preparation of intestinal cleansing. Further research is needed to clarify the factors underlying the differences observed. We believe that trainees should not be included in the screening program; rather only the best performing should carry out screening colonoscopies.

Serious complications of colonoscopy include death, perforation, and bleeding, which is the most frequent. The reported rate of postpolypectomy bleeding ranges from 0.07 to 1.7 % (28), and consistent with this, hemorrhage occurred in 1.1 % of patients in our study. Previous studies have identified various factors associated with postpolypectomy bleeding, including polyp size, location in the right colon, sessile morphology, number of polyps, comorbidities, experience of the endoscopist, number of polyps removed, and use of antiplatelet and anticoagulant drugs [@JR1089-28] .

Rates of CRCs in early stages and treatment by endoscopy were similar in both types of hospitals. In general, CRC polyps are relatively large and difficult to excise. In our program, aspirin at low doses was not withdrawn, while patients on any antiplatelet drugs were switched to aspirin at low doses and anticoagulants were withdrawn. European Society of Gastrointestinal Endoscopy guidelines state that polyps can be safely removed without interruption of aspirin therapy, but there is ongoing debate about polyp removal without interruption of thienopyridines (ticlopidine, clopidogrel, prasugrel, and ticagrelor) and anticoagulants because of the paucity of data available on the safety of the procedure [@JR1089-29] . American College of Chest Physicians guidelines recommend therapy with low-molecular-weight heparin if oral anticoagulants are suspended, depending on thrombotic risk [@JR1089-30] .

In our study, the rate of treatment of patients with CRC by endoscopy was very high (30 %, 785 cases), higher than that reported elsewhere in Europe (23 %) [@JR1089-31] . More than two-thirds of CRCs (70 %) were classified as early-stage disease (N negative), this rate being similar in both types of hospital and similar to that in other screening programmes using FITs. There were no differences in endoscopic treatment by hospital type. The rate of perforation was 1/329 colonoscopies and was associated with colonic diverticular, poor preparation, removal of large polyps (≥ 2 cm) and previous abdominal surgery. In a 2009 review, rates of perforation were found to be 1/1,400 overall and 1 /1,000 for therapeutic colonoscopies [@JR1089-32] . An explanation for the differences may be that studies are generally conducted in referral hospitals or based on datasets in which frequencies may be underestimated. Advanced age, female sex, presence of multiple comorbidities, diverticulosis, and bowel obstruction have previously been shown to increase risk of perforation [@JR1089-33] . Varying perforation rates have been estimated for polypectomies, endoscopic mucosal resections, and endoscopic submucosal dissections.

Non-academic hospitals had the highest rate of ADR and therefore a higher rate of polypectomies. This increases risk of bleeding and explains differences in rates of this complication between hospital types. Nevertheless, no differences were found in risk of colon perforation by hospital type, probably because the risk of this type of complication is much lower.

The limitations of our study include that it was not prospective, the aim was not to determine risk of complications, and withdrawal time was not recorded. On the other hand, its strengths include the population-based approach without selection of hospitals or endoscopists, which means that the data reflect routine clinical practice. Further, the percentage of colonoscopies that were not analyzed due to patients going to private hospitals was low (6.6 %). Finally, a registry database was developed and initiated in a systemic structured manner, using internationally accepted standards to report medical descriptions and diagnoses, and this facilitates uniform identification of CRC cases.

Conclusion
==========

In conclusion, we believe that screening colonoscopies can be performed in non-academic hospitals with similar results to those obtained in academic hospitals.
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